Hyperphosphatemia Therapeutics – Pipeline Analysis 2018, Clinical Trials & Results

Hyperphosphatemia is a medical condition which involves increased level of serum phosphate concentration in the blood. Phosphate is required for bone and cell formation, genetic coding and energy metabolism. An individual is said to have hyperphosphatemia, if the phosphate concentration increasing beyond > 4.5 mg/dL (> 1.46 mmol/L).  Similar to calcium, vitamin D is required to properly absorb phosphate.

Download the sample report @ https://www.pharmaproff.com/request-sample/1138

The various causes of hyperphosphatemia include excessive intake of phosphate, inadequate excretion of phosphates, hypothyroidism, high vitamin D levels, and injuries causing muscle damage. Signs and symptoms associated with the hyperphosphatemia include renal osteodystrophy, secondary hyperparathyroidism and ectopic calcification. Hyperphosphatemia can be treated with phosphate binders, vitamin D analogs, and dietary restriction of phosphate.

Get the detailed analysis @ https://www.pharmaproff.com/report/hyperphosphatemia-therapeutics-pipeline-analysis

Chugai Pharmaceutical Co. Ltd. is developing EOS789 as an oral formulation for the treatment of hyperphosphatemia. Some of the other companies developing hyperphosphatemia therapeutics include Ardelyx Inc., and OPKO Health Inc.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1138

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:

Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com

Web: https://www.pharmaproff.com

Connect with us on: LinkedIn | Twitter | Facebook

Matched content

Editor’s pick

Express Press Release Distribution